E

Can we add fire to the immune system with TIGIT?

A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer

June 1, 2020
E

Will the next generation SERDs make an impact in ER+ HER2- breast cancer?

An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer

May 21, 2020
E

ASCO20 Preview on the importance of modality in oncology R&D

Does modality matter in oncology drug development and if so, where?

May 19, 2020
E

Putting some colour on the TIGIT niche

A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.

May 12, 2020
E

New directions in adenosine axis targeting

A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview

May 7, 2020
E

Flying high in the DDR oncology niche

New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.

May 5, 2020
E

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020
E

Standing out from the crowd

One particular presentation stood out from the others at AACR20 this year

April 29, 2020
E

Postcard 2 on Adoptive Cell Therapies from the AACR20 Virtual Meeting

In our latest postcard from AACR20 virtual meeting we take a look at the adoptive cell therapy plenary session

April 28, 2020
E

Postcards from Day 1 of AACR20

Commentary on Day 1 of the AACR20 Virtual Meeting

April 28, 2020
E

One swallow does not a summer make

Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20

April 27, 2020
E

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020
E

Reflections on new developments in the KRAS niche

Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2

April 20, 2020
E

AACR Preview 2 – Pathways to Success in Targeted Therapies

A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies

April 16, 2020
E

Every cloud has a silver lining

What to watch out for at AACR20 - the first of our meeting previews is here!

April 15, 2020
E

Impact of Covid–19 on Cancer Conferences

A look at the revised schedule and timelines for upcoming Spring cancer conference season

April 13, 2020
E

Time is ticking on the bromodomain landscape

Where are they now four years on? A look at the BET/Bromodomain landscape

April 3, 2020
E

Exploring the immunological links between lung cancer and Covid–19

Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?

March 31, 2020
E

When oncology and coronavirus worlds collide

Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus

March 4, 2020